D
tocol and consent form used in this trial were approved by each participating center's institutional review board; and the study was conducted in accordance with the Declaration of Helsinki. 20 Eligible patients had to be at least 18 years of age, have an SAH confirmed by computerized tomography (CT) scan or lumbar puncture, have an angiographically confirmed saccular aneurysm as the cause of the hemorrhage, and be able to begin treatment with the study drug within 48 hours of the onset of SAH. Patients with all grades of neurological severity were eligible. Patients were excluded if they had a fusiform, traumatic, or mycotic aneurysm; a severe, concomitant medical, neurological, or psychiatric illness; or a serious cardiovascular complication (severe, recent (Ͻ 6 months), uncontrolled hypertension or any Q-wave myocardial infarction, serious cardiac arrhythmia, or congestive heart failure); they were also excluded if they were pregnant or lactating; were taking corticosteroids or any calcium antagonist other than nimodipine prior to randomization; or had a known intolerance to calcium antagonists.
Treatment Methodology
After initial evaluation had been performed and informed consent obtained from the patient or legally appropriate representative, eligible patients were randomly assigned in an equal ratio to receive either vehicle; tirilazad, 0.6 mg/kg per day; tirilazad, 2 mg/kg per day; or tirilazad, 6 mg/kg per day. All preparations were mixed in identical volumes to preserve blinding in the case of both patients and investigators. Randomization was stratified by center to achieve a balance in the frequency of administration of other ancillary therapies, such as antifibrinolytic drugs. The study drug was administered intravenously every 6 hours from entry up to Day 10 following SAH (Day 0 = calendar day of SAH). All patients were treated with intravenously administered nimodipine titrated to a dose of 2 mg per hour for 14 days following SAH. At the discretion of the operating surgeon, a course of oral nimodipine, 60 mg every 4 hours, was continued until Day 21 following SAH. Induced hypertension, intentional hypervolemia, and/or hemodilution therapy for symptomatic vasospasm were allowed as necessary. Balloon or pharmacological angioplasty was also allowed if deemed appropriate, but was considered an endpoint (see below). Other experimental therapies for vasospasm were prohibited. Treatment with steroids or other calcium antagonists during the period of study drug administration was also prohibited. The timing of surgery was selected according to the discretion of the operating neurosurgeon.
The primary endpoint of the trial was the incidence of ischemic symptoms attributed to delayed cerebral vasospasm (symptomatic vasospasm), which was diagnosed using clinical criteria described previously. 7 Computerized tomography scanning of the head was used to exclude other causes. Cerebral angiography and/or transcranial Doppler ultrasonography were encouraged, but not required, to confirm the diagnosis. The incidence of neurological worsening during the treatment period was also monitored. Neurological worsening was defined as a twoor-more point decline in the daily modified Glasgow Coma Scale 12 score (both sides were rated on the motor score, not just the best side) or a two-or-more point increase in the motor score on the National Institutes of Health (NIH) Stroke Scale 13 that persisted for at least 8 hours. When neurological worsening was recognized, the investigators were required to designate a primary cause and all contributing causes, as well as the treatment initiated. The use of cerebral angioplasty for treatment of symptomatic vasospasm was allowed, but subsequent data on arterial narrowing obtained using angiography or transcranial Doppler ultrasonography in patients treated by angioplasty were censured.
The incidence and severity of angiographic vasospasm was assessed by means of follow-up cerebral angiograms obtained from Days 7 through 11 after SAH, the time of peak incidence of angiographic vasospasm. Selected anteroposterior and lateral films from baseline and followup angiograms were copied and sent to the Central Registry at the University of Virginia where they were interpreted by a single blinded investigator. The severity of vasospasm was graded as mild, moderate, or severe, as previously described. 8 Additionally, transcranial Doppler ultrasonography was performed at least every other day from patient entry until Day 14. The maximum mean blood flow velocity from both the right and left middle cerebral arteries was recorded.
Overall outcome was assessed 3 months after SAH by means of the Glasgow Outcome Scale (GOS).
11 Neurological outcome was evaluated using the NIH Stroke Scale. 13 A follow-up CT scan of the head was obtained at 3 months and sent to the Central Registry for blinded interpretation and measurement of infarct volume using planimetric techniques.
Statistical Analyses
An intent-to-treat analysis was performed on all patients receiving at least one dose of study medication. For categorical baseline and efficacy endpoints, including crude mortality at 3 months, a chi-square analysis was used to test for treatment effect. For continuous baseline and efficacy endpoints, a one-way analysis of variance (ANOVA) was used to test for treatment effect. For key baseline and efficacy endpoints (for example, incidence of symptomatic vasospasm, 3-month GOS score, or incidence of cerebral infarction), three preplanned, pair-wise comparisons were made to test for differences between the vehicle-and each tirilazad-treated group. Because the vehicle-treated group was used in each comparison, the tests were not independent and a Bonferroni-adjusted significance level of 0.0167 was adopted for each comparison.
14 This ensured that the overall significance level of 0.05 was maintained. Mortality at 3 months was examined using a Kaplan-Meier survival analysis with a log-rank comparison. Finally, in addition to the primary analysis of all dosed patients, outcome analyses were performed for four prespecified subgroups: patients admitted in good neurological status (Grades I-III), patients admitted in poor neurological status (Grades IV-V), men, and women. Admission neurological status was assessed using a modified version of the World Federation of Neurological Surgeons grading scale. 2 In the modified version, the worst limb motor score tested rather than the best limb motor score was calculated into the Glasgow Coma Scale.
Thus, a total score of 15 points equals Grade I; 13 to 14, Grade II; 9 to 12, Grade III; 6 to 8, Grade IV; and 3 to 5 equals Grade V. Untestable items received an imputed score of 1 point.
Results
From December 1991 through May 1993, 1023 patients were enrolled in the trial. Eight patients (three individuals randomized to vehicle, one patient to 0.6 mg, three to 2 mg, and one to 6 mg tirilazad) were dropped from the study prior to receiving any study medication and were, therefore, excluded from the analysis. The patients were selected from 2840 patients presenting with SAH on admission to the participating centers during that period. The most frequent reasons for exclusion were admission more than 48 hours after SAH (45%) and no saccular aneurysm found (24%). Table 1 shows that the admission characteristics of the patients were similar among the groups, except that there were slightly fewer women in the group receiving 6 mg/kg per day tirilazad (p = 0.08). Prognostic factors for outcome, including admission neurological grade and the proportion of patients with thick subarachnoid clot on CT scan, were also similar among the groups.
Patients in each treatment group were managed in a similar fashion (Table 2) . Over 85% of patients in each group underwent surgical clipping of their ruptured aneurysm, with 50% operated on within the first 48 hours. Intentional hypervolemia, induced hypertension, or intentional hemodilution were used prophylactically in approximately 45% to 50% of patients, with a balance among the treatment groups. Angioplasty for cerebral vasospasm was used infrequently.
At least three-fourths of the patients in each treatment group completed the planned dosage schedule. The main reason for not doing so was death prior to the time dosing was completed ( Table 3 ). The majority of those patients who discontinued treatment because of adverse medical events did so because of increased levels in liver function tests as prescribed by the protocol (see Drug Safety section). Only a small number of patients discontinued treatment after experiencing serious medical events; this number was not significantly different in the four groups. Figure 1 shows the results of an analysis of the primary endpoint, that is, the incidence of symptomatic vasospasm. There was an absolute 8% reduction in the incidence of symptomatic vasospasm in the 6 mg/kg tirilazadtreated group compared to the vehicle-treated group (p = 0.048). The difference was not statistically significant because of multiple comparisons with the vehicle-treated group. The rates in the 0.6 mg/kg and 2 mg/kg tirilazadtreated groups were similar to that of the vehicle-treated group. The use of intentional hypervolemia, induced hypertension, and intentional hemodilution to treat ischemic symptoms from vasospasm was similarly reduced from 18% in the vehicle-treated group to 10% in the 6 mg/kg tirilazad-treated group (p Ͻ 0.01). Finally, there was a reduction in the incidence of clinical cerebral infarction during the 14-day acute observation period from 26% in the vehicle-treated group to 18% in the 6 mg/kg tirilazadtreated group (p = 0.03, not significant).
Neurological worsening from any cause was reported in 42% of vehicle-treated patients and 34% of 6 mg/kg tirilazad-treated patients (p = 0.1, not statistically significant). Table 4 details the primary and contributing causes of neurological worsening determined clinically by the treating investigator. Although neurological worsening from vasospasm was reported less frequently in the 6 mg/kg tirilazad-treated group (p = 0.07, not statistically significant), there was a tendency for fewer reports of worsening from other causes, including rebleeding, hydrocephalus, elevated intracranial pressure, and surgical complications as well.
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Tirilazad in SAH: European/Australasian trial 223 Table 5 lists the proportion of patients in each treatment group with vasospasm as determined by a follow-up cerebral angiogram obtained from Days 7 through 11 after onset of the entry SAH, and the proportion of patients who had elevations in mean middle cerebral artery flow velocities during the treatment period. There were no significant differences among the treatment groups in either indicator of arterial narrowing.
Three-Month Outcome
Three months after SAH, GOS scores were available for all but seven patients (0.7%) (two in the vehicle-treated group, two in the 2 mg/kg tirilazad-treated group, and three in the 6 mg/kg tirilazad-treated group). Eighty-nine percent of patients had follow-up examinations within 91 Ϯ 15 days. Table 6 displays a breakdown of patients' GOS scores by treatment group for all patients receiving either tirilazad or vehicle. The distribution of the outcomes is similar in the vehicle-and the 0.6 mg/kg and 2 mg/kg tirilazadtreated groups. However, the proportion of patients with good recovery was greater (p Ͻ 0.01) and the proportion of patients who died smaller (p Ͻ 0.01) in the 6 mg/kg tirilazad-treated group. There were no significant differences among groups in the proportion of patients with favorable outcome, defined as the combined categories of good recovery or moderate disability. Sixty-four percent of patients treated with 6 mg/kg per day tirilazad were capable of returning to their previous employment compared to 52% of patients treated with vehicle (p = 0.01).
The Kaplan-Meier survival curves are shown in Fig. 2 . The improved survival in the 6 mg/kg tirilazad-treated group was statistically significant (p Ͻ 0.01). Table 7 shows the primary and contributing causes of death or permanent disability by treatment group. There were no statistically significant differences among the treatment groups for any cause, although the proportions were smaller for the group treated with 6 mg/kg tirilazad for most of the causes, including direct effects of the initial SAH and rebleeding.
The mean NIH Stroke Scale score at 3 months in surviving patients was 2.2 Ϯ 5.4 in the 6 mg/kg tirilazadtreated group compared to 2.1 Ϯ 5.3 in the vehicle-treated group. The difference was not statistically significant. Follow-up CT scans at 3 months to measure infarct vol- umes were obtained in only 352 patients. No significant differences in infarct volumes were observed (data not shown), but the groups were not comparable. Examination of the patients' 3-month outcomes by gender disclosed that most of the apparent benefit shown in the 6 mg/kg tirilazad-treated group was attributable to the drug's effects in males (Table 8 ). In the vehicle-treated group, men had a worse outcome than women. Men treated with 6 mg/kg tirilazad had substantially higher good recovery rates and markedly lower mortality than men treated with vehicle, whereas women treated with 6 mg/kg tirilazad did not fare as well as their male counterparts and had outcomes similar to the women treated with vehicle.
Drug Safety
Tirilazad was well tolerated by patients in this study at all three doses. Disorders such as pain or phlebitis at the study drug injection site, an expected complication based on previous safety studies in patients 6 and volunteers, 4, 5 were reported in 1.2% of vehicle-treated and 3.5% of 6 mg/kg tirilazad-treated patients (difference not significant). No patient withdrew from the study because of injection-site reactions. The study drug was discontinued because of elevated levels in liver function tests, as specified in the protocol, in 7.1% of vehicle-treated and 4.7% of 6 mg/kg tirilazad-treated patients. There were no significant differences among the groups in any vital sign, electrocardiogram, or other laboratory parameter, including elevations in creatine kinase. Serious or life-threatening medical events were reported with similar frequency across the treatment groups 
* Outcome is measured using the Glasgow Outcome Scale. 11 "Favorable outcome" is defined as either good recovery or moderate disability. "Unfavorable outcome" is defined as either severe disability, vegetative survival, or death.
† p = 0.01 (tirilazad, 6 mg/kg/day vs. vehicle). * Data presented are proportion of patients who were reported to have one or more causes of death or disability at the 3-month follow up. "Disability" was defined as any outcome other than good recovery on the Glasgow Outcome Scale 11 or death. ( Table 9 ). The only significant difference was a reduction in reports of serious nervous system complications in the 6 mg/kg tirilazad-treated group (15.2%) compared to those in the vehicle-treated group (26.5%, p Ͻ 0.01).
Discussion
These data indicate that addition of intravenous tirilazad, at a dosage of 6 mg/kg per day, to standard care that includes administration of the calcium antagonist nimodipine is associated with an improvement in overall outcome and a reduction in mortality at 3 months in patients with aneurysmal SAH. Although technically this was not the primary endpoint of the study, the importance of this observation should not be undervalued. Overall functional outcome at late follow-up examination is the standard of efficacy for any experimental treatment for patients with ruptured aneurysms. The magnitude of the difference is large and meets rigorous statistical criteria for significance. The apparent benefit is predominantly experienced by men and is present even in cases of men admitted in poor neurological condition (Table 10) .
Although the reduction in the incidence of symptomatic vasospasm in the 6 mg/kg tirilazad-treated group did not reach statistical significance, a strong trend was present (p Ͻ 0.05), and other supportive data indicate that this is a genuine difference. The reduction in the need for rescue treatment using hypertensive/hypervolemic/ hemodilution therapy in the tirilazad groups was highly statistically significant. The reduction in symptomatic vasospasm was also consistent with the observation of reductions in the incidence of cerebral infarction and neurological worsening due to vasospasm. Because the incidence and severity of arterial narrowing were not changed by tirilazad treatment, it is likely that its beneficial effects are mediated through other mechanisms, such as the neuroprotectant effects observed in experimental models of transient focal cerebral ischemia. 19, 21 The observed gender differences in the beneficial effects of 6 mg/kg per day tirilazad treatment pose several interesting questions. One potential explanation for the difference relates to the pharmacokinetics of tirilazad, FIG. 2. Kaplan-Meier survival curves of the four treatment groups beginning with the 1st day of dosing. The difference in 90-day mortality, which favors the 6 mg/kg per day tirilazad-treated group compared to the vehicle-treated group, is statistically significant (p Ͻ 0.01, log-rank comparison). which is metabolized by the p450 enzyme system in the liver. Figure 3 illustrates the area under the curve drug levels for tirilazad and the active first-order metabolite in men and women volunteers of various ages. 3 These data indicate that the blood levels of active tirilazad species may be reduced in young women by as much as 60%. If the minimally effective dose in men is 6 mg/kg per day, it is possible that women may require a substantially higher dose.
The experience in this trial again establishes the safety of tirilazad in doses up to 6 mg/kg per day. The absence of cardiovascular, hemodynamic, or neurological side effects in response to treatment with tirilazad makes use highly compatible with other currently available therapeutic interventions, including calcium antagonists and hypertensive/hypervolemic/hemodilution therapy and angioplasty. Intravenous administration allows for treatment of critically ill patients, even those admitted in poor neurological condition.
Conclusions
The results of this trial represent the first demonstration of the efficacy of a new class of therapeutic agents in the treatment of aneurysmal SAH. Both increased survival and improved functional outcome at 3 months after SAH were observed with treatment of tirilazad at 6 mg/kg per day. The gender differences observed in the drug's beneficial effects, combined with inferences made from gender differences in pharmacokinetics, lead us to suggest that testing of higher doses of tirilazad in patients-particularly women but also men-with SAH is warranted.
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Tirilazad in SAH: European/Australasian trial 227 FIG. 3. Bar graph showing "area under the curve" (AUC) blood levels of total active species, both tirilazad and the active first-order metabolite (U-89678), in men and women volunteers after a single 3 mg/kg intravenous dose. Blood levels of both tirilazad and the active metabolite are reduced in women compared to men.
